Actively Recruiting
Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2026-03-16
139
Participants Needed
1
Research Sites
255 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study evaluated the safety and efficacy of SHR-8068 in combination with Adebrelimab and other anti-tumor drugs in the treatment of advanced renal cell carcinoma
CONDITIONS
Official Title
Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 75 years old (including boundary values)
- Volunteered and signed informed consent
- ECOG performance status score 0-1
- Expected survival of at least 3 months
- Diagnosed with locally advanced unresectable or metastatic clear cell renal cell carcinoma confirmed by histology or cytology
- Provide tumor tissue samples for testing
- Have at least one measurable or evaluable lesion meeting RECIST 1.1 criteria
- Adequate bone marrow and organ function
You will not qualify if you...
- Previously used or currently using HIF inhibitors
- Received chemotherapy, immunotherapy, targeted therapy, anti-tumor traditional Chinese medicine, or other clinical research drugs within 4 weeks before first dose; palliative radiotherapy within 2 weeks before first dose
- Received live attenuated vaccines within the specified period before first medication or expected to need them during treatment
- Undergoing or expecting major surgical treatment during the study period (excluding diagnostic surgery)
- Severe gastrointestinal function abnormalities affecting drug intake or absorption
- Have other active malignant tumors within 3 years or at the same time
- Received organ transplants in the past (excluding corneal transplants)
- Experienced clinically significant thrombotic or embolic event within 6 months before first dose
- Have uncontrolled or poorly controlled heart disease
- Active tuberculosis
- Moderate to severe ascites with symptoms; uncontrolled or moderate to excessive pleural or pericardial effusion
- Toxicity or complications from previous treatments not recovered to NCI-CTCAE grade 1 or lower
- Active hepatitis B or hepatitis C
- Other factors determined by the researcher that may affect study results or cause early study termination
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
Y
Yuting Wang
CONTACT
L
Liang Hu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here